Curatis AG is a specialty pharmaceutical company focused on acquiring, developing and commercialising medicines for the prevention, diagnosis and treatment of rare and specialty‑care diseases. The company operates a distribution business for third‑party orphan and specialty medicines and a development business advancing proprietary drug candidates (e.g., C‑PTBE‑01, C‑AM‑01, C‑MOH‑01, C‑FI‑01) toward clinical development.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Distribution and commercialization of specialty and orphan medicines
Acquisition, licensing, distribution and marketing of medicines for rare and specialty diseases in Switzerland; exclusive distribution rights for numerous products and international partner medicines.
Development of orphan and specialty-care medicines
Development of new specialty and orphan drugs with existing safety and efficacy data; pipeline projects in preclinical and clinical development for rare diseases and conditions with specific care needs.
Commercial partnerships for Switzerland
Tailored partner packages for the commercialization of pharmaceutical products in Switzerland, including market access, registration, pricing, reimbursement, marketing, sales, early-access programmes and pharmacovigilance.
Partnerships for the development of new medicines
Co-development and licensing models for late-stage clinical development projects with biotech, pharma and contract research and manufacturing organizations.
Medicines portfolio
Portfolio of medicines marketed and distributed in Switzerland for pain, oncology, urology, endocrinology, ophthalmology, infectiology, neurology and other therapeutic specialties.